![Isabelle Richard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Isabelle Richard
Directeur Général chez Oger Investissements SAS
Profil
Isabelle Richard is the founder and currently holds the position of Co-Chief Executive Officer at Oger Investissements SAS.
She founded Atamyo Therapeutics SAS in 2020 and holds the position of Chief Scientific Officer.
Postes actifs de Isabelle Richard
Sociétés | Poste | Début |
---|---|---|
Oger Investissements SAS
![]() Oger Investissements SAS Hospital/Nursing ManagementHealth Services Oger Investissements SAS operates as an investment holding company, with interests in the healthcare industry. The company is headquartered in Aix-en-Provence, France. | Directeur Général | - |
Atamyo Therapeutics SAS
![]() Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | Fondateur | 01/01/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Oger Investissements SAS
![]() Oger Investissements SAS Hospital/Nursing ManagementHealth Services Oger Investissements SAS operates as an investment holding company, with interests in the healthcare industry. The company is headquartered in Aix-en-Provence, France. | Health Services |
Atamyo Therapeutics SAS
![]() Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | Health Technology |